National Institute on Drug Abuse; Notice of Closed Meetings, 31770-31771 [2023-10614]
Download as PDF
<![CDATA[
lotter on DSK11XQN23PROD with NOTICES1
31770
Federal Register / Vol. 88, No. 96 / Thursday, May 18, 2023 / Notices
Contact Person: Salma Asmat Quraishi,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Bethesda, MD
20892, (301) 594–0592, salma.quraishi@
nih.gov.
Name of Committee: Cardiovascular and
Respiratory Sciences Integrated Review
Group; Clinical Integrative Cardiovascular
and Hematological Sciences Study Section.
Date: June 15–16, 2023.
Time: 9:00 a.m. to 7:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Margaret Chandler, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4126,
MSC 7814, Bethesda, MD 20892, (301) 435–
1743, margaret.chandler@nih.gov.
Name of Committee: Biobehavioral and
Behavioral Processes Integrated Review
Group; Human Complex Mental Function
Study Section.
Date: June 15–16, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Joanna Szczepanik, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1000D,
Bethesda, MD 20892, (301) 827–2242,
szczepaj@csr.nih.gov.
Name of Committee: Population Sciences
and Epidemiology Integrated Review Group;
Lifestyle and Health Behaviors Study
Section.
Date: June 15–16, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Lisa T. Wigfall, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 1007G,
Bethesda, MD 20892, (301) 594–5622,
wigfalllt@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Training in
Veterinary and Comparative Medicine.
Date: June 16, 2023.
Time: 9:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Raj K. Krishnaraju, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6190,
MSC 7804, Bethesda, MD 20892, (301) 435–
1047, kkrishna@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
VerDate Sep<11>2014
19:05 May 17, 2023
Jkt 259001
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: May 15, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–10650 Filed 5–17–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; Development of Radiation/
Nuclear Medical Countermeasures (MCMs)
and Biodosimetry Devices.
Date: June 13, 2023.
Time: 8:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 5G22,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Michael M. Opata, Ph.D.,
Scientific Review Officer, Scientific Review
Program, Division of Extramural Activities,
National Institute of Allergy and Infectious
Diseases, National Institutes of Health, 5601
Fishers Lane, Room 5G22, Rockville, MD
20852, 240–627–3319, michael.opata@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: May 12, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–10613 Filed 5–17–23; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00102
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; HEAL
Initiative: Rapidly Assessing the Public
Health Impact of Emerging Opioid Threats
(UG1).
Date: June 16, 2023.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Gerald L. McLaughlin,
Ph.D., Scientific Review Officer, Office of
Extramural Policy and Review, National
Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda,
MD 20892, (301) 827–5819, gm145a@nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Toxicological Evaluations of Potential
Medication.
Date: June 29, 2023.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Brian Stefan Wolff, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021,
Rockville, MD 20852, (301) 480–1448,
brian.wolff@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
E:\FR\FM\18MYN1.SGM
18MYN1
Federal Register / Vol. 88, No. 96 / Thursday, May 18, 2023 / Notices
Dated: May 12, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2023–10614 Filed 5–17–23; 8:45 am]
Center for Scientific Review; Amended
Notice of Meeting
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
lotter on DSK11XQN23PROD with NOTICES1
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel; NIAID Investigator Initiated
Program Project Applications (P01 Clinical
Trial Not Allowed).
Date: June 13, 2023.
Time: 12:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F52,
Rockville, MD 20892 (Virtual Meeting).
Contact Person: Lindsey M. Pujanandez,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3F52,
Rockville, MD 20852, (240) 627–3206,
lindsey.pujanandez@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: May 12, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–10616 Filed 5–17–23; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
19:05 May 17, 2023
Jkt 259001
National Institutes of Health
Notice is hereby given of a change in
the meeting of the Center for Scientific
Review Special Emphasis Panel, May
26, 2023, 10:00 a.m. to 2:00 p.m.,
National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
which was published in the Federal
Register on May 3, 2023, FR Doc. No.
2023–09379, 88 FR 27918.
This notice is being amended to
change the Panel Name of the meeting
from Center for Scientific Review
Special Emphasis Panel to Center for
Scientific Review Special Emphasis
Panel PAR–22–233: Time-Sensitive
Opportunities for Health Research. The
meeting is closed to the public.
Dated: May 15, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–10648 Filed 5–17–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Genomic Community Resources.
Date: June 7, 2023.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Room 3189, Bethesda, MD
20892 (Virtual Meeting).
Contact Person: Keith McKenney, Ph.D.,
Scientific Review Officer, National Human
PO 00000
Frm 00103
Fmt 4703
Sfmt 4703
31771
Genome Research Institute, National
Institutes of Health, 6700B Rockledge Drive,
Suite 3000, Bethesda, MD 20892, (301) 594–
4280, mckenneyk@mail.nih.gov.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Nucleic Acid Sequencing Technology.
Date: June 16, 2023.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Room 3189, Bethesda, MD
20892 (Virtual Meeting).
Contact Person: Keith McKenney, Ph.D.,
Scientific Review Officer, National Human
Genome Research Institute, National
Institutes of Health, 6700B Rockledge Drive,
Suite 3000, Bethesda, MD 20892, (301) 594–
4280, mckenneyk@mail.nih.gov.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel; Early Career and Workforce Diversity
in Genomics.
Date: June 20, 2023.
Time: 12:00 p.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Room 3189, Bethesda, MD
20892 (Virtual Meeting).
Contact Person: Sarah Jo Wheelan, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, National Institute for Human
Genome Research, National Institutes of
Health, 6700B Rockledge Drive, Room 3180,
Bethesda, MD 20892, (301) 402–8823
wheelansj@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: May 15, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–10646 Filed 5–17–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Amended Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Heart, Lung,
and Blood Advisory Council, June 6,
2023, 9:00 a.m. to June 6, 2023, 5:00
p.m., National Institutes of Health,
Rockledge I, 6705 Rockledge Drive,
Bethesda, MD 20892 which was
published in the Federal Register on
May 09, 2023, FR Document No. 2023–
09862, 88 FRN 29914.
This notice is being amended to
correct the time for the National Heart,
Lung, and Blood Advisory Council
closed session on June 6, 2023, that was
E:\FR\FM\18MYN1.SGM
18MYN1
]]>Agencies
[Federal Register Volume 88, Number 96 (Thursday, May 18, 2023)]
[Notices]
[Pages 31770-31771]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-10614]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and/or contract proposals
and the discussions could disclose confidential trade secrets or
commercial property such as patentable material, and personal
information concerning individuals associated with the grant
applications and/or contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; HEAL Initiative: Rapidly Assessing the Public Health
Impact of Emerging Opioid Threats (UG1).
Date: June 16, 2023.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate cooperative agreement
applications.
Place: National Institute of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Gerald L. McLaughlin, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, National Institute
on Drug Abuse, NIH, 301 North Stonestreet Avenue, MSC 6021,
Bethesda, MD 20892, (301) 827-5819, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Toxicological Evaluations of Potential Medication.
Date: June 29, 2023.
Time: 11:00 a.m. to 1:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institute of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Brian Stefan Wolff, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural Research,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Rockville, MD 20852, (301) 480-1448, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
[[Page 31771]]
Dated: May 12, 2023.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-10614 Filed 5-17-23; 8:45 am]
BILLING CODE 4140-01-P
